September 2004
European Organisation for Research and Treatment of Cancer
16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNB: any reports involving the topics outlined above are embargoed until the time and date of the news briefingsThe 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics brings 2,000 international cancer experts together to present new data on leading-edge basic, translational and early clinical research.
News briefing:
12.30 hrs CET Wednesday 29 September:
Speakers and topics
* Dr Monika Hegi: Trial identifies which brain cancer patients benefit from temozolomide: genetic predictive test can be carried out in any laboratory and means temozolomide can now become a targeted treatment.
* Dr Ardeshir Ghavamzadeh: Trial results indicate arsenic should now be considered first-line treatment for one type of leukaemia
*Dr Kim Chi: Successful results of Phase I trial of the first second generation antisense cancer drug - phase II getting under way
* Dr Grant McArthur: Award winning researcher reveals potential new role for Glivec in a soft tissue cancer
Chairman: Professor Jaap Verweij (EORTC chairman of conference scientific committee) together with scientific committee co-chairmen Dr Janet Dancey (NCI) and Dr Eric K Rowinsky (AACR)
NB: any reports involving the topics outlined above are embargoed until the time and date of the news briefings.
Journalists wishing to dial in to the news briefing should contact Margaret Willson by Friday 25 September.
More information:
Margaret Willson
Conference Press Officer
Tel: 44-153-677-2181 (office)
44-797-385-3347 (mobile)
Email: [email protected]
Conference media centre:
From 16.00 hrs CET Monday 27 September to 17.00 hrs CET Friday 1 October
Tel: 41-22-761-2205
Fax: 41-22-761-2211
| |
|